Compared to Estimates, Penumbra (PEN) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2025, Penumbra (PEN) reported revenue of $385.39 million, up 22.1% over the same period last year. EPS came in at $1.18, compared to $0.97 in the year-ago quarter.

The reported revenue represents a surprise of +6.74% over the Zacks Consensus Estimate of $361.04 million. With the consensus EPS estimate being $1.12, the EPS surprise was +5.36%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Penumbra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- United States: $299.05 million compared to the $289.07 million average estimate based on three analysts. The reported number represents a change of +20.6% year over year.
• Geographic Revenue- International: $86.33 million compared to the $73.9 million average estimate based on three analysts. The reported number represents a change of +27.7% year over year.
• Revenue- Embolization and Access - International: $34.7 million versus $31.06 million estimated by three analysts on average.
• Revenue- Thrombectomy - International: $51.63 million compared to the $42.84 million average estimate based on three analysts.
• Revenue- Embolization and Access - United States: $95.99 million compared to the $80.72 million average estimate based on three analysts.
• Revenue- Thrombectomy - United States: $203.07 million versus $208.34 million estimated by three analysts on average.
• Revenue- Embolization and Access: $130.69 million versus the three-analyst average estimate of $111.78 million. The reported number represents a year-over-year change of +37%.
• Revenue- Thrombectomy: $254.7 million compared to the $251.19 million average estimate based on three analysts. The reported number represents a change of +15.7% year over year.

View all Key Company Metrics for Penumbra here>>>

Shares of Penumbra have returned -5.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Penumbra, Inc. (PEN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research